Computed tomography characteristics of non-small cell lung cancers with EGFR T790M mutation: role of imaging in the era of precision medicine

Early clinical trials investigating the effectiveness of first generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) demonstrated significant prolongation of survival in patients with non-small-cell lung cancers (NSCLCs) harboring sensitizing mutations (1-3), leading to a major shift in the treatment landscape of NSCLCs.